Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BWAY Brainsway	$12.15 -0.4%	$11.20	$5.98 ▼ $13.66	$229.60M	1.4	68,005 shs	33,092 shs
CATX Perspective Therapeutics	$4.08 +4.6%	$3.14	$1.60 ▼ $16.55	$302.85M	1.18	1.09 million shs	763,541 shs
SMTI Sanara MedTech	$27.89 +2.4%	$29.72	$25.86 ▼ $39.08	$247.89M	1.3	29,903 shs	66,919 shs
SURG SurgePays	$2.95	$2.95	$1.05 ▼ $3.47	$60.21M	0.46	625,817 shs	86,258 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BWAY Brainsway	-0.25%	-5.21%	+11.93%	+46.11%	+76.81%
CATX Perspective Therapeutics	-2.50%	+10.48%	+23.03%	+110.81%	-68.40%
SMTI Sanara MedTech	-5.68%	-10.13%	-5.48%	-5.09%	-8.19%
SURG SurgePays	-1.34%	-13.99%	+14.34%	+24.47%	-3.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BWAY Brainsway	2.6475 of 5 stars	2.5	4.0	2.7	0.8	1.9
CATX Perspective Therapeutics	2.3652 of 5 stars	4.6	1.0	2.2	0.8	0.0
SMTI Sanara MedTech	2.337 of 5 stars	3.5	1.0	3.3	1.7	0.6
SURG SurgePays	3.1661 of 5 stars	3.5	5.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BWAY Brainsway	3.00	Buy	$14.25	17.28% Upside
CATX Perspective Therapeutics	3.18	Buy	$12.56	207.73% Upside
SMTI Sanara MedTech	3.00	Buy	$49.50	77.48% Upside
SURG SurgePays	3.00	Buy	$9.00	205.08% Upside

Current Analyst Ratings Breakdown

Latest SURG, SMTI, CATX, and BWAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/16/2025	SURG SurgePays	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.75 ➝ $9.00
6/9/2025	BWAY Brainsway	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00
5/15/2025	SMTI Sanara MedTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$51.00 ➝ $53.00
5/14/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
5/13/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
4/22/2025	SURG SurgePays	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.50 ➝ $8.75

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BWAY Brainsway	$43.46M	5.28	$0.25 per share	49.07	$3.31 per share	3.67
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
SMTI Sanara MedTech	$91.57M	2.71	N/A	N/A	$4.45 per share	6.27
SURG SurgePays	$60.88M	0.99	N/A	N/A	$0.76 per share	3.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BWAY Brainsway	$2.92M	$0.20	60.75	75.94	N/A	9.01%	7.35%	4.72%	8/5/2025 (Estimated)
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	8/11/2025 (Estimated)
SMTI Sanara MedTech	-$9.66M	-$1.34	N/A	N/A	N/A	-12.48%	-29.22%	-13.20%	8/11/2025 (Estimated)
SURG SurgePays	-$45.73M	-$2.79	N/A	N/A	N/A	-136.37%	-206.01%	-153.67%	8/12/2025 (Estimated)

Latest SURG, SMTI, CATX, and BWAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	SURG SurgePays	-$0.31	N/A	N/A	N/A	$16.14 million	N/A
8/11/2025	N/A	CATX Perspective Therapeutics	-$0.30	N/A	N/A	N/A	$0.17 million	N/A
8/11/2025	Q2 2025	SMTI Sanara MedTech	-$0.33	N/A	N/A	N/A	$25.15 million	N/A
8/5/2025	Q2 2025	BWAY Brainsway	$0.07	N/A	N/A	N/A	$12.34 million	N/A
5/14/2025	Q1 2025	SMTI Sanara MedTech	-$0.31	-$0.41	-$0.10	-$0.41	$23.48 million	$23.43 million
5/13/2025	Q1 2025	BWAY Brainsway	$0.02	$0.04	+$0.02	$0.04	$11.45 million	$11.54 million
5/13/2025	Q1 2025	SURG SurgePays	-$0.40	-$0.38	+$0.02	-$0.38	$9.80 million	$10.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BWAY Brainsway	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
SMTI Sanara MedTech	N/A	N/A	N/A	N/A	N/A
SURG SurgePays	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BWAY Brainsway	N/A	5.03	4.75
CATX Perspective Therapeutics	N/A	9.60	9.60
SMTI Sanara MedTech	1.18	2.77	2.54
SURG SurgePays	0.24	1.72	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BWAY Brainsway	30.11%
CATX Perspective Therapeutics	54.66%
SMTI Sanara MedTech	8.10%
SURG SurgePays	6.94%

Insider Ownership

Company	Insider Ownership
BWAY Brainsway	19.00%
CATX Perspective Therapeutics	3.52%
SMTI Sanara MedTech	42.60%
SURG SurgePays	30.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BWAY Brainsway	120	18.90 million	15.31 million	Not Optionable
CATX Perspective Therapeutics	70	74.23 million	65.21 million	Optionable
SMTI Sanara MedTech	60	8.89 million	5.10 million	Not Optionable
SURG SurgePays	40	20.41 million	14.19 million	Optionable

SURG, SMTI, CATX, and BWAY Headlines

Recent News About These Companies

SurgePays (NASDAQ:SURG) Stock Passes Above 200-Day Moving Average - What's Next?

July 10, 2025 | americanbankingnews.com

SurgePays (NASDAQ:SURG) Stock Passes Above 200-Day Moving Average - Should You Sell?

July 10, 2025 | marketbeat.com

SurgePays Launches New PrePaid Service Smartphones Designed For Convenience Stores And Non-Wireless Retail Channels

July 3, 2025 | twice.comT

SurgePays (NASDAQ:SURG) Share Price Passes Above 200 Day Moving Average - Here's What Happened

July 2, 2025 | marketbeat.com

GPOPlus+ Shareholder Update

June 30, 2025 | accessnewswire.comA

SurgePays launches prepaid phone-in-a-box service for convenience stores

June 27, 2025 | investing.com

SurgePays Launches New Prepaid Service, "Phone-in-a-Box," Designed for Convenience Stores and Non-Wireless Retail Channels

June 26, 2025 | prnewswire.com

SurgePays (NASDAQ:SURG) Share Price Crosses Above Two Hundred Day Moving Average - Here's Why

June 24, 2025 | marketbeat.com

SurgePays (NASDAQ:SURG) Price Target Raised to $9.00

June 16, 2025 | marketbeat.com

SurgePays to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 24-25

June 11, 2025 | prnewswire.com

SurgePays Confirms Directors and Ratifies Accounting Firm

May 20, 2025 | tipranks.com

AT&T (NYSE:T) Partners With Carbyne For APEX Continuity Emergency Solution For PSAPs

May 20, 2025 | finance.yahoo.com

US$8.75 - That's What Analysts Think SurgePays, Inc. (NASDAQ:SURG) Is Worth After These Results

May 17, 2025 | uk.finance.yahoo.com

SurgePays Secures $7M Convertible Note for Expansion

May 16, 2025 | tipranks.com

Why SurgePays, Inc.’s (SURG) Stock Is Down 19.64%

May 15, 2025 | aaii.comA

Q1 2025 Surgepays Inc Earnings Call

May 15, 2025 | uk.finance.yahoo.com

SurgePays, Inc. (SURG) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

SurgePays, Inc. (SURG) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

SurgePays Reports First Quarter 2025 Financial Results

May 13, 2025 | prnewswire.com

SurgePays Announces $7 Million Debt Financing to Accelerate Growth

May 13, 2025 | prnewswire.com

SurgePays to Host First Quarter 2025 Financial Results Conference Call on Tuesday, May 13th

May 6, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Palantir’s Revenue Surge to $1B: Growth vs. Valuation
By Chris Markoch | July 9, 2025
View Palantir’s Revenue Surge to $1B: Growth vs. Valuation
More Than a Monetary Metal: Silver's Case for Outperformance
By Jeffrey Neal Johnson | June 22, 2025
View More Than a Monetary Metal: Silver's Case for Outperformance
Rocket Lab: Latest Catalysts Bolster the Bull Case
By Ryan Hasson | July 3, 2025
View Rocket Lab: Latest Catalysts Bolster the Bull Case

SURG, SMTI, CATX, and BWAY Company Descriptions

Brainsway NASDAQ:BWAY

$12.15 -0.05 (-0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$12.14 -0.01 (-0.08%)

As of 04:04 PM Eastern

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Perspective Therapeutics NYSE:CATX

$4.08 +0.18 (+4.62%)

Closing price 04:00 PM Eastern

Extended Trading

$3.98 -0.10 (-2.33%)

As of 05:19 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Sanara MedTech NASDAQ:SMTI

$27.89 +0.66 (+2.42%)

Closing price 04:00 PM Eastern

Extended Trading

$28.55 +0.66 (+2.37%)

As of 04:09 PM Eastern

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

SurgePays NASDAQ:SURG

$2.95 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.95 0.00 (0.00%)

As of 04:40 PM Eastern

SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time